Estrogen receptor beta is a therapeutic target to improve osteoporotic cortical bone repair in mice: An in-vivo longitudinal study by high-resolution microCT

Bone ◽  
2010 ◽  
Vol 47 ◽  
pp. S406
Author(s):  
Yixin He ◽  
Ge Zhang ◽  
Zhong Liu ◽  
Xiaohua Pan ◽  
Xinhui Xie ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Longitudinal Study ◽  
High Resolution ◽  
Cortical Bone ◽  
Therapeutic Target ◽  
Bone Repair ◽  
Estrogen Receptor Beta ◽  
Receptor Beta

Abstract 1858: Estrogen receptor beta as a tractable therapeutic target

2015 ◽  
Author(s):  
Carly S. Filgueira ◽  
Cindy Benod ◽  
Xiaohua Lou ◽  
Anders Strom ◽  
Jan-Åke Gustafsson ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Therapeutic Target ◽  
Estrogen Receptor Beta ◽  
Receptor Beta

scholarly journals Deletion of Estrogen Receptor Beta in Osteoprogenitor Cells Increases Trabecular but Not Cortical Bone Mass in Female Mice

2015 ◽  
Vol 31 (3) ◽  
pp. 606-614 ◽  
Author(s):  
Kristy M Nicks ◽  
Koji Fujita ◽  
Daniel Fraser ◽  
Ulrike McGregor ◽  
Matthew T Drake ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Bone Mass ◽  
Cortical Bone ◽  
Estrogen Receptor Beta ◽  
Osteoprogenitor Cells ◽  
Female Mice ◽  
Cortical Bone Mass ◽  
Receptor Beta

Assessment of Estrogen Receptor Beta in Patients with Triple Negative Breast Cancer

2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 38-38
Author(s):  
HS Mubisi ◽  
MM Farouk ◽  
II Zaki ◽  
TA El Fayoiem ◽  
AA Ismail
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Lymph Nodes ◽  
Triple Negative Breast Cancer ◽  
Tumor Size ◽  
Therapeutic Target ◽  
Triple Negative ◽  
Estrogen Receptor Beta ◽  
Ki 67 ◽  
Receptor Beta

Introduction: Triple negative breast cancer (TNBC), defined as lacking the expression of estrogen receptor alpha (ERα), progesterone receptor and human epidermal growth factor receptor is an aggressive breast cancer subtype for which there is a need to identify new therapeutic targets. About 50-80% of TNBC express Estrogen Receptor Beta (ERβ). Given its slight differences from ERα in terms of structure, signaling and its anti-proliferative effects on breast cancer cells, ERβ may be a possible therapeutic target. This study sought to assess the presence of ERβ and its correlation with the clinico-pathological features among the Egyptian females with TNBC. Material and Methods: The study was a retrospective analysis. The following data was retrieved from patient’s files and recorded: age, tumor size, lymph nodes metastasis, and stage. Paraffin blocks for patients confirmed by IHC to be TNBC were subjected to immunohistochemical staining for ERβ, CK5/6, and Ki 67. Results: ERβ was positive in 80% of cases (n=32/40). ERβ significantly correlated with Age (rs = -0.473, P = 0.002, n = 40), Tumor size (rs = -0.471, P = 0.007, n = 40), Lymph nodes (rs = -0.365, P = 0.021, n =40), and Stage (rs = -0.468, P = 0.002, n = 40). There was no correlation between ERβ with Ki-67 and CK5/6 a marker of the basal phenotype. All 8 patients without ERβ had an aggressive disease. 4 received neoadjuvant chemotherapy with minimum or no pathologic complete response in the axillary lymph nodes, 2 presented with upfront metastatic disease while the other 2 were cases of local recurrence with a change in the molecular phenotype of the tumor from luminal subtype to TNBC. Conclusion: This study shows ERβ expression occurs in TNBC. It may have the potential to become a therapeutic target for TNBC.

scholarly journals Mind the Gap: Estrogen receptor beta (ERβ) in astrocytes is a therapeutic target to prevent cognitive problems at menopause.

2021 ◽  
Author(s):  
Rhonda Voskuhl ◽  
Noriko Itoh ◽  
Cassandra Meyer ◽  
Yuichiro Itoh ◽  
Darian Mangu ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Cognitive Deficits ◽  
Therapeutic Target ◽  
Brain Aging ◽  
Hormone Replacement ◽  
Unmet Need ◽  
Estrogen Receptor Beta ◽  
Cognitive Testing ◽  
Specific Cell ◽  
Receptor Beta

Abstract Aging is a risk factor for cognitive decline and susceptibility to neurodegenerative diseases. Some aspects of aging, like the loss of sex hormones, may be preventable. Menopause is associated with cognitive deficits and brain atrophy. Since standard hormone replacement therapy (HRT) does not mitigate these brain aging outcomes, a gap in knowledge involves understanding brain region-specific, cell-specific, and receptor-specific mechanisms underlying this neurodegeneration. Here, cognitive testing and in vivo magnetic resonance imaging demonstrated that ovarian hormones in female mice at midlife protect against hippocampal-dependent cognitive impairment and dorsal hippocampal atrophy. Further, this neuroprotection in females at midlife is lost in mice with selective deletion of estrogen receptor beta (ERβ) in astrocytes, but not neurons. This preclinical evidence identifies ERβ in astrocytes as a novel therapeutic target to prevent hippocampal-dependent cognitive deficits and reduce posterior hippocampus atrophy in menopausal women, a major unmet need in half the population.

Sign in / Sign up

Export Citation Format

Share Document